Skip to Content

Zerbaxa Dosage

Generic name: ceftolozane sulfate 1g in 10mL, tazobactam sodium 0.5g in 10mL
Dosage form: injection, powder, lyophilized, for solution

Medically reviewed by Drugs.com. Last updated on Sep 1, 2020.

Recommended Dosage

The recommended dosage of ZERBAXA for injection is 1.5 gram (g) (ceftolozane 1 g and tazobactam 0.5 g) for cIAI and cUTI and 3 g (ceftolozane 2 g and tazobactam 1 g) for HABP/VABP administered every 8 hours by intravenous infusion over 1 hour in patients 18 years or older and with a creatinine clearance (CrCl) greater than 50 mL/min. The duration of therapy should be guided by the severity and site of infection and the patient's clinical and bacteriological progress as shown in Table 1.

Table 1: Dosage of ZERBAXA by Infection in Patients with CrCl Greater than 50 mL/min
Infection Dose Frequency Infusion Time (hours) Duration of Treatment
*
Used in conjunction with metronidazole 500 mg intravenously every 8 hours
Complicated Intra-abdominal Infections* 1.5 g Every 8 Hours 1 4-14 days
Complicated Urinary Tract Infections, Including Pyelonephritis 1.5 g Every 8 Hours 1 7 days
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) 3 g Every 8 Hours 1 8-14 days

Dosage Adjustments in Patients with Renal Impairment

Dose adjustment is required for patients with CrCl 50 mL/min or less (Table 2). All doses of ZERBAXA are administered over 1 hour. For patients with changing renal function, monitor CrCl at least daily and adjust the dosage of ZERBAXA accordingly [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Table 2: Dosage of ZERBAXA in Adult Patients with CrCl 50 mL/min or less
Estimated CrCl
(mL/min)*
Complicated Intra-abdominal Infections and Complicated Urinary Tract Infections, Including Pyelonephritis Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)
*
CrCl estimated using Cockcroft-Gault formula
30 to 50 750 mg (500 mg and 250 mg) intravenously every 8 hours 1.5 g (1 g and 0.5 g) intravenously every 8 hours
15 to 29 375 mg (250 mg and 125 mg) intravenously every 8 hours 750 mg (500 mg and 250 mg) intravenously every 8 hours
End-stage renal disease (ESRD) on hemodialysis (HD) A single loading dose of 750 mg (500 mg and 250 mg) followed by a 150 mg (100 mg and 50 mg) maintenance dose administered every 8 hours for the remainder of the treatment period (on hemodialysis days, administer the dose at the earliest possible time following completion of dialysis) A single loading dose of 2.25 g (1.5 g and 0.75 g) followed by a 450 mg (300 mg and 150 mg) maintenance dose administered every 8 hours for the remainder of the treatment period (on hemodialysis days, administer the dose at the earliest possible time following completion of dialysis)

Preparation of Solutions

ZERBAXA does not contain a bacteriostatic preservative. Aseptic technique must be followed in preparing the infusion solution.

Preparation of doses:

Constitute each vial of ZERBAXA with 10 mL of sterile water for injection or 0.9% Sodium Chloride for Injection, USP and gently shake to dissolve. The final volume is approximately 11.4 mL per vial. Caution: The constituted solution is not for direct injection.

To prepare the required dose, withdraw the appropriate volume determined from Table 3 from the reconstituted vial(s). Add the withdrawn volume to an infusion bag containing 100 mL of 0.9% Sodium Chloride for Injection, USP or 5% Dextrose Injection, USP. For doses above 1.5 g, reconstitute a second vial in the same manner as the first one, withdraw an appropriate volume (per Table 3), and add to the same infusion bag. Discard unused portion.

Table 3: Preparation of Doses
ZERBAXA (ceftolozane and tazobactam) Dose Volume to Withdraw from Reconstituted Vial(s)
3 g (2 g and 1 g) Two vials of 11.4 mL each (entire contents from two vials)
2.25 g (1.5 g and 0.75 g) 11.4 mL from one vial (entire contents) and 5.7 mL from a second vial
1.5 g (1 g and 0.5 g) 11.4 mL (entire contents from one vial)
750 mg (500 mg and 250 mg) 5.7 mL
450 mg (300 mg and 150 mg) 3.5 mL
375 mg (250 mg and 125 mg) 2.9 mL
150 mg (100 mg and 50 mg) 1.2 mL

Inspect drug products visually for particulate matter and discoloration prior to use. ZERBAXA infusions range from clear, colorless solutions to solutions that are clear and slightly yellow. Variations in color within this range do not affect the potency of the product.

Compatibility

Compatibility of ZERBAXA with other drugs has not been established. ZERBAXA should not be mixed with other drugs or physically added to solutions containing other drugs.

Storage of Constituted Solutions

Upon constitution with sterile water for injection or 0.9% sodium chloride injection, reconstituted ZERBAXA solution may be held for 1 hour prior to transfer and dilution in a suitable infusion bag.

Following dilution of the solution with 0.9% sodium chloride or 5% dextrose, ZERBAXA is stable for 24 hours when stored at room temperature or 7 days when stored under refrigeration at 2 to 8°C (36 to 46°F). Discard unused portion.

Constituted ZERBAXA solution or diluted ZERBAXA infusion should not be frozen.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.